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Abstract
Objective—Clinical studies suggest that psychiatric symptoms, particularly depression, anxiety
and trauma, may be associated with inflammation, as indexed by proinflammatory cytokines. Such
a link may be especially significant in pregnancy, and may shed additional light on the etiology of
perinatal mood disorders.
Methods—We prospectively followed 145 women selected from a community obstetric clinic
serving a primarily low-income, high psychosocial risk population. Women without evidence of
medical high-risk pregnancies were screened (including psychiatric and trauma histories) and then
assessed in detail (e.g. mood symptoms) at approximately 18 and 32 weeks gestation. Blood was
drawn to measure key proinflammatory markers, interleukin (IL)-6 and tumor necrosis factor
(TNF)-α. Data on pregnancy and obstetric outcome were derived from medical records.
Results—There was considerable stability of cytokine levels within individuals and a significant
mean increase across pregnancy observed for IL-6 (p<.001) and TNF-α (p<.001). History of
trauma was associated with significantly elevated TNF-α (F(1.135)=4.43, p<.05), controlling for
psychosocial and obstetric covariates. In contrast, elevated measures of depression and anxiety
were unrelated to proinflammatory cytokines (p>.10). Exploratory analyses indicated that neither
psychiatric symptoms nor proinflammatory cytokines predicted birthweight, gestational age, or
obstetric complications.
Conclusions—These findings suggest that antecedent trauma may be associated with
persistently elevated TNF- α levels during pregnancy. No evidence was found that a generalized
proinflammatory state was associated with symptoms of depression or anxiety in pregnant women.
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Introduction
Psychiatric disorders during pregnancy represent a major public health concern because of
their prevalence and persistence into the postpartum period (1, 2). Public health and clinical
concerns about prenatal psychiatric disturbance are most acute for minority women of lower
socioeconomic status who exhibit increased prevalence of depressive symptoms (3–6). For
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example, a large-scale study of low income minority pregnant women reported that 29.3%
(7) had experienced a traumatic event; another study of a similar population reported rates of
post traumatic stress disorder (PTSD) to be 7.7% (8). Markedly elevated rates of co-morbid
depression (42.2% and 66.7%) and anxiety disorders (any anxiety disorder 35.1%, panic
disorder 36.4%) were found in studies by Loveland Cook et al (8) and Smith et al. (7),
respectively.
The pathophysiology underlying mood changes throughout the perinatal period is not fully
understood. Potential mechanisms currently being investigated include genetic vulnerability
(9), disruption of the HPA axis (10, 11), sensitivity to changes in levels of steroid hormones
(11, 12) and other markers of stress including sleep disruption (13, 14). In the current paper,
we consider the hypothesis that prenatal mood disorders may be associated with cytokines
(low molecular weight, circulating messenger proteins) that often promote inflammation
(i.e., proinflammatory cytokines), specifically Tumor Necrosis Factor (TNF)-α and
Interleukin (IL)-6.
Although IL-6 and TNF-α are both involved in immune responses, hematopoeisis, and
inflammation, they are distinct proteins with their own characteristic functional properties
(15). These cytokines are secreted by monocytes/macrophages within the immune system
and other organs. However, TNF-α can be produced by some T helper, Th 1cells, whereas
IL-6 is produced by Th 2 cells. Further, IL-6 is, notably, secreted by adipocytes and
endothelial cells. Although both IL-6 and TNF-α are important components of acute phase
responses to a variety of challenges, there are a number of studies that report low
correlations between these two cytokines (16–19).
A growing body of literature suggests that proinflammatory cytokines may be causally
associated with psychiatric symptoms (20, 21). Evidence for this derives from several
sources involving non-pregnant samples. First, exposure to psychosocial stressors, including
marital difficulties and childhood maltreatment, is associated with inflammation and
proinflammatory cytokine production (22–24). Second, illnesses characterized by chronic
inflammatory responses are also associated with depression (25). Third, the administration
of cytokines such as IFN-α to treat infectious diseases or cancer often results in patients
exhibiting ‘sickness behaviors’ analogous to depressive symptoms; these symptoms ceased
when treatment was stopped, and the symptoms were attenuated with antidepressant
treatment (26–28). A recent meta-analysis found that compared to control subjects, patients
with major depression had significantly higher concentrations of IL-6 and TNF-α (29);
associations with other cytokines were not significant. Studies of cytokines and anxiety
symptoms are fewer and focus particularly on PTSD (30, 31), but also provide robust
evidence that compared to controls, subjects with PTSD have significantly increased levels
of serum IL-6 (32–34) and TNF-α (33, 34).
It is not yet clear whether the link between psychiatric symptoms and proinflammatory
cytokines reported outside of the perinatal period exists during pregnancy, or how this may
help to explain prenatal mood disorders. Pregnancy is characterized by substantial
alterations in endocrine and immune measures with obvious functional importance (35), and
these pregnancy-related changes may disguise or confound a link with psychiatric
symptoms. Available data indicating such relationships are limited, but suggestive.
Coussons-Read et al (36,37) reported a significant association between elevated
psychosocial stress scores and higher levels of IL-6 and TNF-α measured in the first and
third trimesters. Christian et al (38) did not find a significant association between perceived
stress and either IL-6 or TNF-α at 15 weeks gestation, but did report that depressive
symptoms were significantly and positively associated with IL-6 and marginally with TNF-
α. More work is clearly needed to determine if a link exists, whether or not it is evident
Blackmore et al. Page 2













throughout pregnancy, and which symptom patterns are most closely associated with
cytokine production. Accordingly, the central aim of this short-term longitudinal study is to
investigate the link between psychiatric symptoms and proinflammatory cytokines in a
sample of pregnant women using a broad index of psychiatric symptoms.
Considerable evidence associates psychiatric symptoms and stress with low birth weight,
premature labor and delivery, and pregnancy complications (39–47). Therefore, if there is a
link between prenatal psychiatric symptoms and inflammation, as we hypothesized and
studies of non-pregnant women document, then that raises the possibility that symptoms
may predict obstetric outcomes via their association with cytokine production. That follows
reports in the obstetrics literature that inflammation in pregnancy predicts poor obstetric
outcomes (48–51). We consider this an exploratory hypothesis because a very substantial
number of individuals with pregnancy complications may be needed to detect this mediation
(in contrast to the numbers needed to detect associations between symptoms and cytokines,
the central aim of the paper).
In summary, the current study was designed to extend the limited research on psychiatric
symptoms and proinflammatory cytokines in women with a normal pregnancy. We do this
by a) focusing on a broad set of psychiatric dimensions (depression, anxiety and trauma) and
targeting proinflammatory cytokines most reliably assessed in the clinical literature (IL-6
and TNF-α); b) including women at high psychosocial risk, who are typically under-
represented in the literature; and c) assessing women in two occasions of measurement,
during the 2nd and 3rd trimesters, to try to account for the changing nature of both symptoms
and cytokines across pregnancy.
Methods
Design & Study Participants
The data are derived from a prospective, longitudinal cohort study of women receiving
obstetrical care from a hospital-based practice serving a predominantly low income minority
population. We included women who were physically healthy and considered low to
medium obstetric risk as we wanted to examine the link between cytokines and affective
symptoms in a normal, i.e. non-diseased state. High obstetric risk referred to increased
likelihood of maternal or fetal complications due to various factors including young or old
maternal age, more than one fetus, experiencing previous problems in pregnancy
(preeclampsia, stillbirth, multiple miscarriages), drug or alcohol use. Women with existing
medical conditions that would either raise obstetric risk or lead to increased cytokine levels
were also excluded, including autoimmune disorders, high blood pressure, kidney disease
and sexually transmitted diseases. Our inclusion criteria were therefore, women aged 20–34
years old with a confirmed singleton pregnancy less than 18 weeks gestation, considered
low to medium obstetric risk by the medical team, with no existing autoimmune disorders,
fluent in English and able to provide informed consent. Women diagnosed with bipolar
disorder or schizophrenia were excluded. We obtained screening data on 214 women who
were interested in participating in a pregnancy-related research study and willing to provide
blood samples. Sixty-nine of these 214 women were excluded upon further interview. Fifty-
two women had at least one exclusion criteria, including having autoimmune conditions not
detected in the initial screen, being considered at increased obstetric risk, or presence of
psychotic features. Seventeen women failed to complete both assessments; 9 relocated out of
state or were lost to contact, and 8 experienced a perinatal loss or delivered prior to the 32
week assessment. We therefore report on a final sample of 145 women who completed
assessments at both 18 and 32 weeks gestation. Data were collected between May 2007 and
April 2010.
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The study was approved by the University of Rochester Research Subjects Review Board.
Written informed consent was obtained from each research participant following an
explanation of the study procedures.
Procedure and Measures
The women were interviewed by trained clinical interviewers and completed a battery of
questionnaires and a clinical diagnostic interview at approximately 18 and 32 weeks
gestation. Interviews took place in the University of Rochester Clinical Research Center,
located within the same hospital from which they received their obstetric care; blood was
also obtained during these assessments. Detailed clinical, medical and sociodemographic
data were obtained from case notes.
Depression—Depressive symptomatology was assessed using the Edinburgh Postnatal
Depression Scale [EPDS] (52) the most widely used and validated screening tool for
depressive symptoms in pregnant and postpartum women (53). Validation studies showed
that a score of 13 on the EPDS identifies women with a diagnosis of major depression(54,
55), while a cut-off of ≥9 has been used within community samples to also include probable
cases of minor depression. Clinical diagnoses of current depression and history of past
depressive episodes were obtained through administration of the mood episodes section of
the SCID (56), a widely used diagnostic assessment to assess clinical disorder.
Anxiety—Anxiety symptoms were assessed using the 20-item state subscale of the State-
Trait Anxiety Inventory [STAI] (57), a widely used measure of anxiety in pregnancy in
obstetric and psychological settings. The anxiety section of the SCID was completed to
generate categorical diagnoses; Generalized Anxiety Disorder, Specific and Social Phobias,
Obsessive Compulsive Disorder (OCD) and Panic Disorder were assessed. Exposure to
traumatic events was categorized based on the responses given within the PTSD section; for
those subjects reporting a traumatic event that met criterion A, each event and the age at
which it occurred were described. Lifetime diagnoses of PTSD were made according to
DSM-IV criteria.
Adverse Obstetric Outcomes—Obstetric outcomes were defined according to standard
definitions, and their occurrence assessed from maternal and infant clinical case notes by a
board certified specialist in Obstetrics & Gynecology and Maternal Fetal Medicine (EKP).
The outcomes of interest were: premature labor and delivery (<37 weeks gestation), low
birth weight (<2500g), growth restriction (<10th percentile for gestational age), preterm
premature rupture of membranes (<37 weeks and prior to onset of labor), preeclampsia,
intra-uterine infection, placental abruption, gestational diabetes and rates of Caesarean
sections, including those that were emergent (unscheduled) due to imminent maternal or
fetal harm. We consider both number and type of events and a dichotomous index of any
adverse obstetric outcome in analyses below.
Laboratory Procedures & Cytokine Analysis—The majority of blood samples were
obtained between 8am and 2pm, although 14 samples were collected between 2pm and 4pm.
Those women providing blood samples later in the afternoon did so at both time points.
Blood was collected into vacutainer tubes (BD Diagnostics, Franklin Lakes, NJ) via
conventional venipuncture. Blood was centrifuged at 1000g for 10 min within 15 minutes of
collection and serum aliquoted into 4 cryovials to avoid repeat freeze-thaw cycles for
testing. Serum was stored at −80°C until assayed. In order to ensure that elevated cytokines
levels were not due to an underlying medical condition or infection, women were asked
prior to the blood draw if they had been ill recently, the nature of any illness and any
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medications that they had taken. Women who had been febrile, experienced a cold or flu or
were taking medications for these were asked to return a week later, or when asymptomatic,
to provide blood and complete assessments; we also investigated medical chart data for
evidence of illness.
Serum levels of IL-6 and TNF-α were assayed with enzyme-linked immunoassay (ELISA)
using high-sensitivity kits purchased from R&D Systems, Inc. (Minneapolis, MN). The kits
were used according to manufacturer’s standard protocols with the standard curve run on
each 96-well assay plate. Samples were run in duplicate. Absorbance was read at 490 nm
with 650 nm wavelength correction within 30 minutes after development using an
automated Opsys MR Microplate Reader (Thermo Labsystems, Chantilly, Virginia). The
minimum detectable limit for IL-6 is 0.039 pg/ml and 0.106 pg/ml for TNF-α. The intra-
assay variability for both cytokines is approximately 4% and the inter-assay CV was <5%.
Data analysis
Subjects excluded due to elevated cytokine levels—Fifteen subjects had IL-6 and/
or TNF-α levels that were highly elevated at 18 or 32 weeks gestation. In 6 cases, inspection
of the medical notes showed that these individuals were being treated for infections that
arose around the time of the blood draw and so these cases were excluded. However, we
could not account for the remaining subjects with substantially clinically elevated cytokine
levels, but presumed that the levels implied an undetected medical concern or idiopathic
condition. We subsequently excluded subjects with IL-6 and TNF-α values >3 SD above the
mean, resulting in N’s of 130 and 137 subjects for analysis, respectively.
Covariates—Based on previous findings in the literature and following recent reviews (58)
we included the following as covariates: maternal age, body mass index (BMI; calculated
using the standard formula from the data taken at the initial intake when pregnancy-related
weight gain is still very modest), education, Medicaid status, marital status, sleep (self-rated
quality of sleep ranging from very bad to very good and the total number of hours slept in a
typical night) (59) and the time of the blood draw. Number of hours of sleep and the time of
the blood draw were included to control for circadian rhythm.
After reporting descriptive data, we report the associations between proinflammatory
cytokines and individual health and socio-demographic factors previously linked with
antenatal depression to determine which variables are important covariates for the main
analyses. Analyses to examine the link between psychiatric symptoms and cytokines make
use of the continuous (questionnaire) and categorical (SCID diagnosis) psychiatric data. We
had no a priori predictions about the timing in pregnancy, and so we first report, for
exploratory purposes, bivariate associations at each assessment. However, given the stability
of individual differences across measurements, the most appropriate test is a repeated
measures analysis of variance with time (18 and 32 weeks gestation) as a within-subjects
factor and psychiatric symptoms (plus potential covariates) as between-subjects factors. That
also allowed for the formal test of whether or not an association was significantly stronger in
mid- than late-gestation. Repeated measures of analysis also models the dependence or
within-individual correlation in measures over time. Meditational analyses were planned to
test the hypothesis that psychiatric symptoms predicted obstetric outcomes via a shared link
with cytokines (see below).
Cytokine levels were not normally distributed; the data were log transformed for subsequent
analyses. Correlations between IL-6 and TNF-α across pregnancy were <.10; consequently,
they were treated separately in analyses of psychiatric and obstetric data.
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Descriptive data, shown in Table 1, indicate that the sample was at generally high
psychosocial risk of mood disorders, indexed by the high rates of minority status, low
education, non-married status, Medicaid receipt, and age at first pregnancy.
Psychiatric data (see Table 2) confirm this impression: 15.2% and 11.2% of women met
DSM criteria for minor or major depression at 18 and 32 weeks gestation respectively;
38.6% of women scored ≥9 and 20% >12 on the EPDS at 18 weeks, while at 32 weeks
28.2% scored ≥9 and 12% were >12. Thirty-two percent of women met criteria for an
anxiety disorder (excluding PTSD) during pregnancy and over a third (37.2%) had been
exposed to a traumatic event, with 11% having a lifetime diagnosis of PTSD.
Analyses were conducted both with and without the blood samples that were collected
between 2–4 pm; similar results were obtained in both analyses and so we report data based
on the whole sample (e.g., the correlation between time of assessment and cytokine levels
were r=−0.02 and r=0.12 for IL-6 and r=−0.07 and r=0.09 for TNF-α at 18 and 32 weeks).
Table 3 shows mean levels of IL-6 and TNF-α at both points. Both cytokines increased
significantly across pregnancy and showed significant intra-individual stability across time.
For descriptive purposes we present significant correlations between cytokine levels and
health and sociodemographic factors. We found that BMI was significantly positively
correlated with IL-6 at both times in pregnancy (r=0.45 p<.001 at 18 weeks, and 0.37 p<.
001at 32 weeks gestation).
For IL-6 at 18 weeks gestation we found significant negative correlations with age at first
pregnancy (r(130)= −0.20, p<0.05) and number of hours of sleep (r(121)=−0.22, p<0.02).
We also found that, at 18 but not 32 weeks gestation, parous women had higher mean levels
of IL-6 (values in pg/ml) than those without children (1.04 (0.36) vs 0.91 (0.39); (F
1,128)=4.20, p<0.05) and white women had lower levels of IL-6 compared with minority
women (0.87 (0.48) vs 1.01 (0.34); F 1,128=5.90, p<0.02). IL-6 at 32 weeks gestation was
significantly negatively correlated with number of years of education (r(130) = −0.21, p<.
02.
The only significant finding for TNF-α was between age at first pregnancy and TNF-α levels
at 18 weeks gestation (r(137)= −.23, p<.01). We consider these covariates in the analyses
below.
Psychiatric Symptomatology & Cytokines—There was no evidence of a significant
link between depressive symptoms and IL-6 in pregnancy. Bivariate correlations between
EPDS continuous scores and IL-6 were <r =.10; categorical analyses using SCID-based
diagnoses of Major Depressive Disorder (MDD) or a broader phenotype that included minor
depression and the NOS designation yielded a similar lack of association. Repeated
measures analysis of variance, which capitalized on the power of the repeated assessments,
showed no significant association between depression (F(1,128)=1.00, p>.10) or depressive
symptoms and IL-6 (F(1, 128)=1.15, p>.10). Moreover, whereas we observed a sizeable
increase in IL-6 across pregnancy (Table 3), the mean level of depressive symptoms on the
EPDS decreased (Table 2), providing yet further evidence of a disconnect between
depression and IL-6. Parallel analyses for TNF-α also revealed a lack of association and
very small effect size (F 1,135)p>.96; F (1,135)p>.23). See Table 4 for mean, standard
deviations and effect sizes for depression and cytokine analyses.
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There was no evidence of a significant association between anxiety and IL-6 or TNF-α,
according to the continuous measure (STAI) or categorical diagnoses of any anxiety
disorder, excluding PTSD, from the SCID (see Table 4). These findings were unchanged
when we repeated the above analyses controlling for BMI, ethnicity, number of children,
time of blood draw, age at first pregnancy, and education.
We did, however, observe a significant association between trauma and TNF-α. Repeated
measures of analysis of variance indicated a main effect of trauma exposure and TNF-α
(F(1,135)=4.43 p<.05); the effect of time was also significant (F(1, 135)=18.63 p<0.001),
but there was no significant interaction between time and trauma exposure in predicting
TNF-α levels (F(1, 135)=0.36; p>.20; Figure 1). The main effect of trauma exposure
remained significant after controlling for covariates (time of blood draw, age at first
pregnancy, maternal age, ethnicity, education), including co-occurring depression and
anxiety.
Further analyses of the trauma exposed group (n=54) found no link between the age at first
trauma and TNF-α level. We found that TNF-α and lifetime clinical diagnosis for PTSD
(n=16) were less strongly linked when compared to those women with trauma exposure but
no PTSD diagnosis In a repeated measures analysis of variance, the effect of PTSD
diagnosis was not significant (F(1,135)= 1.75, p>.20), with time remaining significant
(F(1,135)=11.80, p<0.001) and no significant time × diagnosis interaction.
We did not find a significant association between trauma exposure or PTSD diagnosis and
IL-6, when parallel repeated measures analyses were conducted (details available from the
first author).
Obstetric Outcomes—Psychiatric symptoms and diagnoses at either point in pregnancy
did not predict obstetric outcomes (birthweight, gestational age, complications); correlation
coefficients did not exceed r=.15. Neither did we obtain a significant association between
IL-6 or TNF-α and birthweight, gestational age, or complications (r’s < .15 in absolute
value). Given the lack of prediction of obstetric outcomes, we did not pursue the
multivariate analyses linking psychiatric symptoms, cytokines, and obstetric outcomes.
Discussion
The hypothesis that proinflammatory cytokines may be involved in the pathophysiology of
psychiatric symptoms is gaining considerable momentum and is supported by both animal
and human data. Nonetheless, the mechanisms underlying this connection and its application
to treatment remains largely unresolved. We extended this line of investigation to the
prenatal period in a short-term longitudinal study that followed a sample of women at high
psychosocial risk, but with normal pregnancies.
We found no relationship between IL-6 and TNF-α at either time point in pregnancy,
supporting the findings of previous studies of pregnant (16–18) and non-pregnant samples
(19). Although IL-6 and TNF-α are both proinflammatory cytokines and play a major role in
the acute phase response, they do differ functionally and so the lack of association is not
wholly surprising.
We found limited but robust evidence of a link between trauma exposure and elevated TNF-
α; no other reliable link between symptoms and proinflammatory cytokines was detected.
The current study provides a first documentation in pregnancy of an association between
trauma and TNF-α, a cytokine that is among the most widely-investigated in the psychiatric
literature. This extends prior work linking trauma and proinflammatory cytokines in non-
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pregnant samples (30–33, 60) in suggesting that one of the effects of trauma exposure may
be inflammation. In this study, the elevated proinflammatory marker associated with past
trauma persisted throughout pregnancy and was found despite the substantial normative
changes in immunological markers (and many others besides) that occur in pregnancy. It is
notable that the effect observed here is comparable to that observed in the non-pregnant
samples (see above). We are unable to specify the mechanism linking trauma exposure and
TNF-α levels, but several candidates exist and require further study (see 61).
Exposure to stressors, including traumatic events, leads to alteration of the sympathetic and
parasympathetic nervous systems and the hypothalamic-pituitary-adrenal (HPA) axis (62).
The bidirectional relationship between the HPA axis and immune system can be disrupted as
a consequence (62–64), leading to greater proinflammatory immune responsiveness (65). It
may be that for women that have been exposed to a traumatic event the elevated
proinflammatory state persists despite the immunosuppression ordinarily seen during
pregnancy (35). However, we need to further examine the relationship between cytokines
and trauma exposed women in both the postpartum period and a non-pregnant state.
Compared to previous studies of pregnant women and depressive symptoms (14,36,37) we
report higher levels of IL-6 and lower levels of TNF-α in our sample. Our observation of
small effect sizes, in some cases opposite to that predicted, between IL-6 and mood
symptom ratings also contrasts with previous studies of non-pregnant individuals (29, 33,
60). There are several possible explanations for this discrepancy. One is pregnancy itself. As
noted, pregnancy-induced changes in IL-6, which resulted in a change of approximately
one-third of a standard deviation from approximately 18 to 32 weeks gestation, may have
confounded an association that would be otherwise detected (i.e., outside of pregnancy).
That is not wholly convincing, however, because two studies did report an association
between IL-6 and self-reported symptoms and stress in pregnancy, although the psychiatric
phenotype assessed differed between studies (stress versus depressive symptoms) (36, 38).
Another possibility for these apparent differences in both cytokine levels and their link with
depression between studies is that our sample differed; these women were at particular
psychosocial risk due to factors associated with low SES (less years of education, single,
Medicaid recipients) and almost half were from a minority group. Whether these factors
may disrupt a link between IL-6 and mood symptoms remains to be determined, and will
require further follow-up into the postnatal period.
We did not find support for our exploratory hypotheses. TNF-α, which was associated with
trauma, did not predict obstetric outcome; neither did IL-6 nor the other symptom measures.
That was an important set of analyses to conduct because previous studies suggested that
trauma-exposed woman may have worse obstetric outcomes (66). Birth outcomes were
included in our framework because they were not included in previous studies of symptoms
and cytokines (36–38) and it is clearly important to examine if the overlap between
symptoms and cytokines accounted for a link between psychiatric symptoms and obstetric
risk. This null finding must be seen as preliminary, however, because significant prediction
from prenatal symptoms to obstetric outcome are typically derived from large community
samples, and documenting a mediation effect may similarly require very large samples.
Also, we excluded medically medium-high risk pregnancies and so we have excluded the
population for whom the psychiatric symptom and proinflammatory cytokine link may be
most easily detected. A further consideration is that, as we and others have found, apparently
normal samples almost inevitably include individuals with substantially elevated cytokines.
It is certainly possible that previously observed relationships may not be demonstrable under
pathophysiological conditions. Quite apart from the biological explanation is the practical
issue of how these apparently “extreme” cases are best handled.
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Our study is limited in that we focused on low medical risk pregnancies and so had a low
base rate of adverse outcomes; large scale studies may be required to show effects of
psychiatric symptoms or increased inflammation on adverse outcomes. Balancing these
limitations are several strengths, including the moderately sized sample, multiple occasions
of measurement from pregnancy to birth outcome, detailed symptom and psychiatric
assessments, inclusion of several potential confounds of cytokine levels, and focus on
specific biomarkers of inflammation.
The study provides data on the link between cytokines and mood symptoms during
pregnancy. The finding of TNF-α predicting trauma exposure in pregnant women requires
further investigation as it may be a potential predictor of affective disturbance in the
postpartum period.
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Mean levels of TNF-alpha across gestation by trauma exposure status. Standard error bars
are shown.
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Table 1
Key sociodemographic and clinical variables of the sample.
Variable M (SD) range or % (n)
Age at interview (years) 24.67 (3.66) 20–34
Age at first pregnancy (years) 19.52 (4.01) 11–34
First pregnancy ≤ 18 years old 48.3% (70)
Total number of pregnancies 1.71(1.62) 0–8
Is this the first pregnancy?
Yes 29.0% (42)






Years completed 12.73(2.27) 8–26
Did not finish high school 20.7% (30)
Completed high school 41.4% (60)
Some college 25.5% (37)
Completed college 12.4% (18)
Ethnicity
White/Caucasian 29.0% (42)




BMI 28.06 (7.61) 13.0–49.4
Underweight (<18.5) 5.5 % (8)
Normal (18.5–24.9) 37.9 % (55)
Overweight (25.0–29.9) 23.4 % (34)





Receiving Medicaid 70.3% (102)
Low birthweight <2500g * 6.3% (9)
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Variable M (SD) range or % (n)
Premature delivery <37 weeks * 3.5% (5)
Intrauterine growth restriction* 4.9% (7)
Premature Rupture of Membranes* 1.4% (2)
Preeclampsia* 4.2% (6)
Placental Abruption* 1.4% (2)
Gestational Diabetes* 5.6% (8)
Rates of Caesarean-sections* 19.0% (27)
Emergent Caesarean-sections 25.9% (7/27)
*
Sample n=142 for these variables, for all others n=145.
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Table 2
Psychiatric diagnoses and symptoms across pregnancy.
Psychiatric Diagnosis/Symptoms Mean (SD) range or % (n)
Major Depressive Episode
18 weeks 6.9% (10)
32 weeks 6.3% (9)
Minor depression or NOS
18 weeks 8.3% (12)
32 weeks 4.9% (7)
Self-reported history of depressive episode 46.9% (68)
EPDS Score
18 weeks 7.23 (5.99) 0–23
32 weeks 5.90 (5.32) 0 – 24
>12 at 18 weeks 20.0% (29)
>12 at 32 weeks 12.0% (17)
Diagnosis of Any Anxiety Disorder in Pregnancy excluding PTSD 31.7% (46)
Lifetime Diagnosis of PTSD 11% (16)
Met criterion A for PTSD 37.2% (54)
Age at first traumatic exposure (years) 15.74 (6.49) 4–29
Exposure to trauma <18 years old 64.8% (35)
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Table 3





Statistics from Time 1 to Time 2.
IL-6 0.99 (0.38) 1.16 (0.37) t=6.21, df=129, p<0.001.
r=0.66, 130, p<0.001.
TNF-α 0.44 (0.41) 0.55 (0.45) t=4.30, df=136, p<0.001
r=0.73, 137, p<0.001
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Table 4
Bivariate analysis of mean levels of cytokines (pg/ml) by PTSD diagnostic category and gestation point with
effect size (Cohen’s d).
IL-6 (n=130) TNF-α (n=137)













Yes 1.07 (0.43) 1.26 (0.44) 0.53 (0.39) 0.71 (0.44)
No 0.98 (0.37) 1.14 (0.36) 0.43 (0.41) 0.53 (0.45)
d=0.22 d=0.30 d=0.25 d=0.40
Trauma Exposure according to PTSD criterion A
Yes 1.02 (0.39) 1.18 (0.39) 0.52 (0.45) 0.66 (0.51)
No 0.97 (0.36) 1.14 (0.36) 0.39 (0.37) 0.49 (0.41)
d=0.13 d=0.11 d=0.32 d=0.37
*
N’s for those meeting PTSD lifetime criteria diagnostic criteria: IL-6=15, TNF-α=16 and criterion A of PTSD (IL-6=50, TNF-α=53).
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